<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01528150</url>
  </required_header>
  <id_info>
    <org_study_id>CR-11-054-EU-LV</org_study_id>
    <nct_id>NCT01528150</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Tendril MRI™ Leads in Standard Bradycardia Pacing Indication</brief_title>
  <acronym>TendrilMRI™</acronym>
  <official_title>Clinical Investigation to Assess the Safety and Efficacy of the Tendril MRI™ Leads, as a Part of the Accent MRI™ System, in Patients With Standard Bradycardia Pacing Indication.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this observational study is the assessment (safety and efficacy) of the St.
      Jude Medical Tendril MRI™ leads. The Tendril MRI™ leads are a full part of the Accent MRI™
      System, consisting of Tendril MRI™ leads and Accent MRI™ pacemaker. The subject population
      includes patients with a standard bradycardia pacing indication.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Magnetic resonance imaging (MRI) is a diagnostic method to view high quality two and three
      dimensional images of the body. However, magnetic resonance imaging systems generate three
      electromagnetic fields that are used to produce an image. These include a static magnetic
      field, a time varying gradient magnetic field, and a radiofrequency field. All three of these
      fields interact with implanted devices and could create hazards for the device, the patient,
      or both. Due to these issues, currently marketed pacemaker systems may be contraindicated for
      use in an MRI environment.

      St. Jude Medical has developed a system, the Accent MRI™ system, comprised of the Accent MRI™
      device and the Tendril MRI™ lead, and an investigational MRI Activator™, designed to mitigate
      such interactions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Freedom From RA and RV Lead-related Complications</measure>
    <time_frame>up to 12 months post-implant</time_frame>
    <description>Safety of the Accent MRI™ system with the Tendril MRI™ lead will be evaluated in terms of freedom from Right Atrial (RA) and Right Ventricular (RV) lead-related complications for the acute (implant to 2 month visit) and chronic (2 month visit through the 12 month visit) timeframes.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">466</enrollment>
  <condition>Bradycardia</condition>
  <arm_group>
    <arm_group_label>Accent MRI System</arm_group_label>
    <description>Accent MRI system will be implanted = Accent MRI Pacemaker + Tendril MRI Leads</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        standard bradycardia indications
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Approved Class I or Class II indication per: European Society of Cardiology (ESC)
             guidelines for implantation of a dual chamber pacemaker or single chamber pacemaker,
             OR American College of Cardiology (ACC) / American Heart Association (AHA) / Heart
             Rhythm Society (HRS) guidelines for implantation of a dual chamber pacemaker or single
             chamber pacemaker

          -  Require a new Accent MRI™ pacemaker and Tendril MRI™ lead (either initial implant or
             complete system change out with no abandoned devices).

          -  Is ≥ 18 years of age.

          -  Able to provide written informed consent prior to any investigational related
             procedure.

          -  Willing and able to comply with the prescribed follow-up tests and schedule of
             evaluations.

        Exclusion Criteria:

          -  Have an existing pacemaker or ICD (abandoned devices and/or leads are not allowed. A
             new pacemaker and lead or complete system change out is required for enrollment).

          -  Have an existing active implanted medical device (e.g., Implantable Cardioverter
             Defibrillator (ICD), neurostimulator, etc.).

          -  Have a non-MRI compatible device or material implant (e.g., intracranial aneurysm
             clip, non-MRI compatible devices or material, metals or alloys, etc.).

          -  Have a lead extender, plug or adaptor.

          -  Have a prosthetic tricuspid heart valve.

          -  Are currently participating in another investigational device or drug investigation.

          -  Are allergic to Dexamethasone sodium phosphate (DSP).

          -  Are pregnant or planning to become pregnant during the duration of the study.

          -  Have a life expectancy of less than 12 months from Screening due to any
             life-threatening condition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rob RW Breedveld, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Center Leeuwarden, the Netherlands</affiliation>
  </overall_official>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2012</study_first_submitted>
  <study_first_submitted_qc>February 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2012</study_first_posted>
  <results_first_submitted>December 2, 2015</results_first_submitted>
  <results_first_submitted_qc>July 19, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 31, 2016</results_first_posted>
  <last_update_submitted>March 8, 2018</last_update_submitted>
  <last_update_submitted_qc>March 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bradycardia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Accent MRI System</title>
          <description>Accent MRI system will be implanted = Accent MRI Pacemaker + Tendril MRI Leads</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="466"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="422"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Accent MRI System</title>
          <description>Accent MRI system will be implanted = Accent MRI Pacemaker + Tendril MRI Leads</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="466"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.74" spread="11.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="194"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>AtrioVentricular-Block (AV-Block)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No AV Block</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st Degree AV Block</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2nd Degree AV Block</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3rd Degree AV block</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sick Node Dysfunction</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Sick Node Dysfunction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Sick Node Dysfunction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Neurocardiogenic Syncope</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Previous Neurocardiogenic Syncope</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Previous Neurocardiogenic Syncope</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="391"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Freedom From RA and RV Lead-related Complications</title>
        <description>Safety of the Accent MRI™ system with the Tendril MRI™ lead will be evaluated in terms of freedom from Right Atrial (RA) and Right Ventricular (RV) lead-related complications for the acute (implant to 2 month visit) and chronic (2 month visit through the 12 month visit) timeframes.</description>
        <time_frame>up to 12 months post-implant</time_frame>
        <population>A total of 464 patients were implanted. 463 patients (99.78%) were implanted with Accent MRI™ systems with the Tendril MRI™ leads while the remaining 1 patient (0.22%) was implanted with a device that was not an Accent MRI™ system. This patient was excluded from all primary endpoint analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Accent MRI System</title>
            <description>Accent MRI system will be implanted = Accent MRI Pacemaker + Tendril MRI Leads</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From RA and RV Lead-related Complications</title>
          <description>Safety of the Accent MRI™ system with the Tendril MRI™ lead will be evaluated in terms of freedom from Right Atrial (RA) and Right Ventricular (RV) lead-related complications for the acute (implant to 2 month visit) and chronic (2 month visit through the 12 month visit) timeframes.</description>
          <population>A total of 464 patients were implanted. 463 patients (99.78%) were implanted with Accent MRI™ systems with the Tendril MRI™ leads while the remaining 1 patient (0.22%) was implanted with a device that was not an Accent MRI™ system. This patient was excluded from all primary endpoint analyses.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>97.5% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="463"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Acute Timeframe (Implant to 2 Months)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.19" lower_limit="94.94" upper_limit="98.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic Timeframe (&gt;2 Months to 12 Months)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.14" lower_limit="97.58" upper_limit="99.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Data collection on adverse events were collected from Enrollment until 12M follow up, i.e. 1 year.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Accent MRI System</title>
          <description>Accent MRI system will be implanted = Accent MRI Pacemaker + Tendril MRI Leads</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="174" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Exacerbation of heart failure</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Other Cardiac/cardiovascular</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Exacerbation of Diabetes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infection</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>hematoma/bleeding</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>other various</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muskuloskeletal event</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>neoplastic disease</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>neurological event</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>renal event</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax/hemothorax</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Pulmonary events</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Device migration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Helix issue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Impedance out of range</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>lead dislodgement or migration</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Lead replacement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Other lead related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac/Venous Perforation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>arrhythmia</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>exacerbation of heart failure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>other cardio/cardiovascular</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>hematoma/bleeding</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Decreased right ventricular sensing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>device programming</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>impedance out of range</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>lead noise</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>other various</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Other lead related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Pacemaker software issue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>musculoskeletal event</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>neurological event</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pulmonary event</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director Clinical Studies</name_or_title>
      <organization>St. Jude Medical</organization>
      <phone>+1 818 493 3648</phone>
      <email>aoza@sjm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

